Therapy Area topics
Cardiovascular
Alnylam shoots for the heart
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
Thought CETP inhibition was dead? Think again
New Amsterdam wants to prove that the ill-fated mechanism has a role in cardiovascular disease – and this time it’s all about the bad cholesterol.
Diabetes
The next generation of diabetes technology
New devices are coming, but the real advances will involve combinations.
Go or no go? Lilly’s valuable diabetes contender
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
Digital Health
Akili plays the Spac game for $1bn
But, judging by similar transactions, the valuation might not stay that high for long.
Oncology
Atara’s is the latest setback for a troubled field
Bayer dumps Atara, Precigen prepares for a fire sale and Tmunity struggles to find direction. Should investors still be excited about cell therapy?
Abbvie takes its Treg cue
The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.
EHA 2022 preview – some good news at last
Positive data result in positive share price movements – something of a novelty in the current market.
Respiratory
Asset resuscitation fails to resuscitate Mereo
Mereo claims another success with a big pharma castoff, but its win in alpha 1-antitrypsin deficiency is questionable.
Glaxo gets a Shingrix boost
But pressure is on the shingles vaccine as the consumer spin-off approaches.
Various
Go or no go? Bristol's first-in-class hopes
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
Significant readouts for small players
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
